Magenbypass

Magenbypass is the German term for what is internationally known as the Roux-en‑Y gastric bypass, a surgical intervention used primarily to treat morbid obesity and related metabolic conditions. The operation reduces the functional volume of the stomach by creating a small pouch from the upper part, while redirecting the small intestine so that food bypasses a substantial portion of the stomach and duodenum. This dual mechanism leads to both restriction of food intake and malabsorption of nutrients, resulting in significant weight loss and improvement or remission of type 2 diabetes, hypertension, sleep apnea and other obesity‑related illnesses.

The procedure was first described in the 1950s and gained widespread adoption in the 1990s after improvements in surgical technique and postoperative care. In a typical operation, the stomach is divided to create a pouch about 50–100 milliliters in capacity. A segment of the jejunum is then connected to this pouch, forming a bypass loop that reroutes ingested food into the small intestine and reattaches the flow of bile and pancreatic enzymes further downstream. This configuration preserves the liver and gallbladder, which reduces pancreatitis risk compared with other bypass variations.

Pre‑operative assessment includes nutritional evaluation, psychological screening and determination of comorbidities. Post‑operative care focuses on gradual re‑introduction of foods, vitamin supplementation, and regular follow‑up to monitor weight loss trajectory and detect complications such as dumping syndrome or marginal ulcers.

Efficacy data from registries indicate an average excess weight loss of 60–70 % over two to five years, with a high proportion of patients achieving remission of type 2 diabetes. Nevertheless, the surgery carries risks—bleeding, infection, nutritional deficiencies and rare mortality—and is recommended for patients with a body mass index above 35 kg/m² or even lower when severe comorbidities are present. Alternative weight‑loss interventions include sleeve gastrectomy, endoscopic procedures and pharmacotherapy, each with distinct risk‑benefit profiles.